Preston G C, Ward C, Lines C R, Poppleton P, Haigh J R, Traub M
Neuroscience Research Centre, Merck, Sharp & Dohme, Essex, UK.
Psychopharmacology (Berl). 1989;98(4):487-94. doi: 10.1007/BF00441947.
The muscarinic antagonist scopolamine and the benzodiazepine lorazepam both produce transient impairments in memory and attention in normal volunteers. These impairments can be reversed by appropriate agents such as the cholinesterase inhibitor physostigmine in the case of scopolamine or the benzodiazepine antagonist Ro 15-1788 in the case of lorazepam. In this paper we investigated the pharmacological specificity of these reversals by examining the interactions of scopolamine and Ro 15-1788 and of lorazepam and physostigmine. There was no evidence that the effects of scopolamine and lorazepam on cognitive function could be attenuated by Ro 15-1788 and physostigmine, respectively. The results are discussed in terms of pharmacological models of Alzheimer's disease.
毒蕈碱拮抗剂东莨菪碱和苯二氮䓬类药物劳拉西泮都会使正常志愿者的记忆力和注意力出现短暂损害。这些损害可通过适当药物逆转，如在东莨菪碱的情况下使用胆碱酯酶抑制剂毒扁豆碱，在劳拉西泮的情况下使用苯二氮䓬拮抗剂Ro 15 - 1788。在本文中，我们通过研究东莨菪碱与Ro 15 - 1788以及劳拉西泮与毒扁豆碱之间的相互作用，来探究这些逆转作用的药理学特异性。没有证据表明Ro 15 - 1788和毒扁豆碱能分别减弱东莨菪碱和劳拉西泮对认知功能的影响。我们根据阿尔茨海默病的药理学模型对结果进行了讨论。
